Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
19 NC counties are under alert, including Wake, Durham, Johnston, Orange, and Wayne counties.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Edgewise Therapeutics Inc
(NQ:
EWTX
)
21.68
+0.83 (+3.98%)
Streaming Delayed Price
Updated: 3:27 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
442,397
Open
20.96
Bid (Size)
21.66 (3)
Ask (Size)
21.69 (2)
Prev. Close
20.85
Today's Range
20.60 - 21.70
52wk Range
5.120 - 23.50
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Via
Investor's Business Daily
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
May 13, 2024
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.
Via
Investor's Business Daily
Performance
YTD
+97.09%
+97.09%
1 Month
+33.99%
+33.99%
3 Month
+40.32%
+40.32%
6 Month
+123.74%
+123.74%
1 Year
+203.22%
+203.22%
More News
Read More
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
May 10, 2024
From
Edgewise Therapeutics
Via
Business Wire
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
May 09, 2024
Via
Benzinga
Edgewise Therapeutics: Q4 Earnings Insights
February 22, 2024
Via
Benzinga
How Is The Market Feeling About Edgewise Therapeutics?
January 31, 2024
Via
Benzinga
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
May 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
May 06, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
April 23, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April 15, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March 27, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
March 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
February 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
February 13, 2024
From
Edgewise Therapeutics
Via
Business Wire
Insider Favorites: 7 Stocks with Bullish Buying Signals
February 11, 2024
Via
InvestorPlace
Insiders Buying Edgewise Therapeutics And 2 Other Stocks
January 26, 2024
Via
Benzinga
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
What's Going On With Edgewise Therapeutics Stock?
January 19, 2024
Via
Benzinga
World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday
January 19, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
January 19, 2024
From
Edgewise Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.